As several families are gathering this week for the holidays, unfortunately some are spending them at our area hospitals.

Atara Biotherapeutics, Inc. disclosed in a recent 8-K filing with the Securities and Exchange Commission that on December 20, 2024, the Board of Directors approved the amendment and restatement of the ...

Fintel reports that on December 20, 2024, Rodman & Renshaw initiated coverage of Atara Biotherapeutics (NasdaqGS:ATRA) with a ...

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

It is possible that AtLP represent multiclonal B cells, T cells or NK-cell lymphoproliferative processes in which there is an existence of occult abnormal B-cell, T-cell or NK-cell clones.

Immunosuppressive treatment is considered for autoimmune, inflammatory and lymphoproliferative disorders that frequently develop in CVID. Bronchopulmonary hygiene measures and pulmonary ...

After hours: December 24 at 2:52:48 PM EST Loading Chart for ATRA ...

He co-founded a non-profit that advocates for First Nations ownership interests in pipelines, critical minerals mines, clean ...